CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models
Executive Summary
CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.
You may also be interested in...
Medicare Part B And Accelerated Approvals: MedPAC Mulls Use Of CED Versus Payment Caps
Medicare advisory panel discusses ongoing issues around launch prices that were not addressed by the government price controls targeting older drugs enacted as part of the Inflation Reduction Act.
Medicare Price Negotiation Process Could Adapt Private Sector ‘Best Practices,’ Official Suggests
CMS principal deputy administrator Jonathan Blum discusses how the agency is thinking about implementing the drug pricing reforms now under consideration in the US Congress.
Medicare Premium Hike Will Help Build ‘Contingency Fund’ For Alzheimer’s Drugs
But CMS cautions that the announcement should not be read as a preview of its upcoming national Medicare coverage decision on Aduhelm and similar treatments.